UBS Group initiated coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) in a research note issued on Tuesday, Briefing.com reports. The firm set a “buy” rating and a $111.00 price target on the stock. UBS Group’s price objective would suggest a potential upside of 21.31% from the stock’s current price.
AXSM has been the subject of a number of other reports. Royal Bank of Canada started coverage on Axsome Therapeutics in a report on Thursday, January 25th. They issued an “outperform” rating and a $126.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $180.00 target price on shares of Axsome Therapeutics in a research report on Tuesday, December 26th. Cantor Fitzgerald restated an “overweight” rating and issued a $108.00 price target on shares of Axsome Therapeutics in a report on Monday, January 22nd. Citigroup started coverage on shares of Axsome Therapeutics in a research note on Wednesday, December 13th. They issued a “buy” rating and a $125.00 price target for the company. Finally, Piper Sandler increased their price objective on shares of Axsome Therapeutics from $90.00 to $113.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $113.10.
Read Our Latest Research Report on Axsome Therapeutics
Axsome Therapeutics Trading Down 1.4 %
AXSM opened at $91.50 on Tuesday. Axsome Therapeutics has a twelve month low of $53.71 and a twelve month high of $94.96. The company has a fifty day moving average of $80.15 and a 200-day moving average of $73.61. The stock has a market cap of $4.33 billion, a PE ratio of -20.20 and a beta of 1.21. The company has a quick ratio of 4.38, a current ratio of 4.46 and a debt-to-equity ratio of 0.66.
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last issued its quarterly earnings results on Monday, November 6th. The company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.08). The business had revenue of $57.79 million for the quarter, compared to analyst estimates of $54.88 million. Axsome Therapeutics had a negative return on equity of 88.79% and a negative net margin of 90.33%. During the same quarter in the previous year, the business posted ($1.03) earnings per share. On average, sell-side analysts predict that Axsome Therapeutics will post -4.14 EPS for the current year.
Institutional Trading of Axsome Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the stock. Truist Financial Corp bought a new stake in Axsome Therapeutics during the fourth quarter worth $1,678,000. State of New Jersey Common Pension Fund D boosted its holdings in Axsome Therapeutics by 17.2% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 38,049 shares of the company’s stock worth $3,028,000 after acquiring an additional 5,576 shares during the last quarter. New York State Common Retirement Fund raised its holdings in shares of Axsome Therapeutics by 12.2% in the fourth quarter. New York State Common Retirement Fund now owns 28,047 shares of the company’s stock valued at $2,232,000 after purchasing an additional 3,052 shares during the last quarter. Handelsbanken Fonder AB lifted its position in shares of Axsome Therapeutics by 13.2% during the fourth quarter. Handelsbanken Fonder AB now owns 7,700 shares of the company’s stock valued at $613,000 after purchasing an additional 900 shares in the last quarter. Finally, Phocas Financial Corp. bought a new position in shares of Axsome Therapeutics during the fourth quarter valued at about $2,140,000. 76.60% of the stock is owned by hedge funds and other institutional investors.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
See Also
- Five stocks we like better than Axsome Therapeutics
- Dividend Capture Strategy: What You Need to Know
- This mid-cap tech stock just jumped 30%…and is still cheap
- How to Invest in Toy Stocks
- 3 companies that more than doubled analyst EPS estimates
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Commvault launches to new highs; more highs to come
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should you invest $1,000 in Axsome Therapeutics right now?
Before you consider Axsome Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Axsome Therapeutics wasn’t on the list.
While Axsome Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Do you expect the global demand for energy to shrink?! If not, it’s time to take a look at how energy stocks can play a part in your portfolio.
